U.S. Markets close in 3 hrs 1 min

Biostage, Inc. (BSTG)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.87000.0000 (0.00%)
As of 9:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.8700
Open2.8700
BidN/A x N/A
AskN/A x N/A
Day's Range2.8700 - 2.8700
52 Week Range1.7900 - 4.8800
Volume112
Avg. Volume1,321
Market Cap24.914M
Beta (5Y Monthly)-0.14
PE Ratio (TTM)N/A
EPS (TTM)-1.1250
Earnings DateMay 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Biostage Reports First Quarter 2020 Financial Results
    PR Newswire

    Biostage Reports First Quarter 2020 Financial Results

    Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing bioengineered organ implants based on the Company's novel Cellspan™ technology, today announced its financial results for the three months ended March 31, 2020.

  • Biostage Reports 2019 Financial Results
    PR Newswire

    Biostage Reports 2019 Financial Results

    Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing next-generation esophageal implants, today announced its financial results for the three and twelve months ended December 31, 2019.

  • Biostage Announces IND Approval from FDA for its Lead Product Candidate Cellspan™ Esophageal Implant
    PR Newswire

    Biostage Announces IND Approval from FDA for its Lead Product Candidate Cellspan™ Esophageal Implant

    Biostage, Inc. (OTCQB: BSTG) (Biostage or the Company), a bioengineering company developing next-generation esophageal implants, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug application (IND) for the Cellspan Esophageal Implant (CEI) to treat patients with end-stage esophageal disease that require a segmental surgical resection to repair the diseased tissue. The FDA notified the Company that it removed the clinical hold and that the Company may proceed with its study.